Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters










Database
Language
Publication year range
1.
Sci Adv ; 8(29): eabm7833, 2022 07 22.
Article in English | MEDLINE | ID: mdl-35857833

ABSTRACT

Subunit vaccines inducing antibodies against tumor-specific antigens have yet to be clinically successful. Here, we use a supramolecular α-helical peptide nanofiber approach to design epitope-specific vaccines raising simultaneous B cell, CD8+ T cell, and CD4+ T cell responses against combinations of selected epitopes and show that the concurrent induction of these responses generates strong antitumor effects in mice, with significant improvements over antibody or CD8+ T cell-based vaccines alone, in both prophylactic and therapeutic subcutaneous melanoma models. Nanofiber vaccine-induced antibodies mediated in vitro tumoricidal antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). The addition of immune checkpoint and phagocytosis checkpoint blockade antibodies further improved the therapeutic effect of the nanofiber vaccines against murine melanoma. These findings highlight the potential clinical benefit of vaccine-induced antibody responses for tumor treatments, provided that they are accompanied by simultaneous CD8+ and CD4+ responses, and they illustrate a multiepitope cancer vaccine design approach using supramolecular nanomaterials.


Subject(s)
Cancer Vaccines , Melanoma , Nanofibers , Animals , Epitopes , Immunity, Cellular , Mice , Peptides
2.
J Immunother Cancer ; 8(1)2020 04.
Article in English | MEDLINE | ID: mdl-32273346

ABSTRACT

BACKGROUND: First-in-human (FIH) clinical trials require careful selection of a safe yet biologically relevant starting dose. Typically, such starting doses are selected based on toxicity studies in a pharmacologically relevant animal model. However, with the advent of target-specific and highly active immunotherapeutics, both the Food and Drug Administration and the European Medicines Agency have provided guidance that recommend determining a safe starting dose based on a minimum anticipated biological effect level (MABEL) approach. METHODS: We recently developed a T cell activating bispecific antibody that effectively treats orthotopic patient-derived malignant glioma and syngeneic glioblastoma in mice (hEGFRvIII:CD3 bi-scFv). hEGFRvIII:CD3 bi-scFv is comprized of two single chain antibody fragments (bi-scFvs) that bind mutant epidermal growth factor receptor variant III (EGFRvIII), a mutation frequently seen in malignant glioma, and human CD3ε on T cells, respectively. In order to establish a FIH dose, we used a MABEL approach to select a safe starting dose for hEGFRvIII:CD3 bi-scFv, based on a combination of in vitro data, in vivo animal studies, and theoretical human receptor occupancy modeling. RESULTS: Using the most conservative approach to the MABEL assessment, a dose of 57.4 ng hEGFRvIII:CD3 bi-scFv/kg body weight was selected as a safe starting dose for a FIH clinical study. CONCLUSIONS: The comparison of our MABEL-based starting dose to our in vivo efficacious dose and the theoretical human receptor occupancy strongly supports that our human starting dose of 57.4 ng hEGFRvIII:CD3 bi-scFv/patient kg will be safe.


Subject(s)
Antibodies, Bispecific/administration & dosage , Antibodies, Monoclonal/administration & dosage , CD3 Complex/immunology , ErbB Receptors/immunology , Glioma/drug therapy , Models, Theoretical , Animals , Apoptosis , Cell Proliferation , Computer Simulation , Dose-Response Relationship, Drug , Drug Dosage Calculations , Drug Evaluation, Preclinical , Female , Glioma/immunology , Glioma/pathology , Humans , Mice , Tumor Cells, Cultured , Xenograft Model Antitumor Assays
3.
Clin Cancer Res ; 25(1): 358-368, 2019 01 01.
Article in English | MEDLINE | ID: mdl-30425092

ABSTRACT

PURPOSE: Chimeric antigen receptor (CAR) T cells have shown promise against solid tumors, but their efficacy has been limited, due in part, to immunosuppression by CD4+FoxP3+ regulatory T cells (Tregs). Although lymphodepletion is commonly used to deplete Tregs, these regimens are nonspecific, toxic, and provide only a narrow window before Tregs repopulate hosts. Importantly, CARs have also been shown to inadvertently potentiate Tregs by providing a source of IL2 for Treg consumption. We explored whether disruption of the IL2 axis would confer efficacy against solid tumors without the need for lymphodepletion. EXPERIMENTAL DESIGN: We developed second- (CD28z) and third- (CD28-4-1BBz) generation CARs targeting EGFRvIII. To eliminate secretion of IL2, 2 amino acid substitutions were introduced in the PYAP Lck-binding motif of the CD28 domain (ΔCD28). We evaluated CARs against B16 melanomas expressing EGFRvIII. RESULTS: CD28z CARs failed to engraft in vivo. Although 4-1BB addition improved expansion, CD28-4-1BBz CARs required lymphodepletion to treat solid tumors. CARs deficient in Lck signaling, however, significantly retarded tumor growth without a need for lymphodepletion and this was dependent on inclusion of 4-1BB. To evaluate CAR vulnerability to Tregs, we lymphodepleted mice and transferred CARs alone or with purified Tregs. Cotransfer with Tregs abrogated the efficacy of CD28-4-1BBz CARs, whereas the efficacy of ΔCD28-4-1BBz CARs remained unperturbed. CONCLUSIONS: In the absence of lymphodepletion, CARs targeting solid tumors are hindered by Treg immunosuppression and poor persistence. Here, CARs were modified to circumvent Treg suppression and to simultaneously improve in vivo engraftment. Modified CARs treated solid tumors without a need for lymphodepletion.


Subject(s)
CD28 Antigens/genetics , Neoplasms/therapy , Receptors, Chimeric Antigen/therapeutic use , Tumor Necrosis Factor Receptor Superfamily, Member 9/genetics , Animals , CD28 Antigens/immunology , Heterografts , Humans , Immunotherapy, Adoptive , Interleukin-2/genetics , Interleukin-2/immunology , Mice , Neoplasms/immunology , Neoplasms/pathology , Receptors, Chimeric Antigen/immunology , Signal Transduction , T-Lymphocytes, Regulatory/immunology , T-Lymphocytes, Regulatory/pathology , Tumor Necrosis Factor Receptor Superfamily, Member 9/immunology
4.
Oncoimmunology ; 7(6): e1434464, 2018.
Article in English | MEDLINE | ID: mdl-29872570

ABSTRACT

Adoptive transfer of T cells expressing chimeric antigen receptors (CARs) is an effective immunotherapy for B-cell malignancies but has failed in some solid tumors clinically. Intracerebral tumors may pose challenges that are even more significant. In order to devise a treatment strategy for patients with glioblastoma (GBM), we evaluated CARs as a monotherapy in a murine model of GBM. CARs exhibited poor expansion and survival in circulation and failed to treat syngeneic and orthotopic gliomas. We hypothesized that CAR engraftment would benefit from host lymphodepletion prior to immunotherapy and that this might be achievable by using temozolomide (TMZ), which is standard treatment for these patients and has lymphopenia as its major side effect. We modelled standard of care temozolomide (TMZSD) and dose-intensified TMZ (TMZDI) in our murine model. Both regimens are clinically approved and provide similar efficacy. Only TMZDI pretreatment prompted dramatic CAR proliferation and enhanced persistence in circulation compared to treatment with CARs alone or TMZSD + CARs. Bioluminescent imaging revealed that TMZDI + CARs induced complete regression of 21-day established brain tumors, which correlated with CAR abundance in circulation. Accordingly, TMZDI + CARs significantly prolonged survival and led to long-term survivors. These findings are highly consequential, as it suggests that GBM patients may require TMZDI as first line chemotherapy prior to systemic CAR infusion to promote CAR engraftment and antitumor efficacy. On this basis, we have initiated a phase I trial in patients with newly diagnosed GBM incorporating TMZDI as a preconditioning regimen prior to CAR immunotherapy (NCT02664363).

5.
Clin Cancer Res ; 24(15): 3611-3631, 2018 08 01.
Article in English | MEDLINE | ID: mdl-29703821

ABSTRACT

Purpose: Conventional therapy for malignant glioma fails to specifically target tumor cells. In contrast, substantial evidence indicates that if appropriately redirected, T cells can precisely eradicate tumors. Here we report the rational development of a fully human bispecific antibody (hEGFRvIII-CD3 bi-scFv) that redirects human T cells to lyse malignant glioma expressing a tumor-specific mutation of the EGFR (EGFRvIII).Experimental Design: We generated a panel of bispecific single-chain variable fragments and optimized design through successive rounds of screening and refinement. We tested the ability of our lead construct to redirect naïve T cells and induce target cell-specific lysis. To test for efficacy, we evaluated tumor growth and survival in xenogeneic and syngeneic models of glioma. Tumor penetrance following intravenous drug administration was assessed in highly invasive, orthotopic glioma models.Results: A highly expressed bispecific antibody with specificity to CD3 and EGFRvIII was generated (hEGFRvIII-CD3 bi-scFv). Antibody-induced T-cell activation, secretion of proinflammatory cytokines, and proliferation was robust and occurred exclusively in the presence of target antigen. hEGFRvIII-CD3 bi-scFv was potent and target-specific, mediating significant lysis of multiple malignant glioma cell lines and patient-derived malignant glioma samples that heterogeneously express EGFRvIII. In both subcutaneous and orthotopic models, well-engrafted, patient-derived malignant glioma was effectively treated despite heterogeneity of EGFRvIII expression; intravenous hEGFRvIII-CD3 bi-scFv administration caused significant regression of tumor burden (P < 0.0001) and significantly extended survival (P < 0.0001). Similar efficacy was obtained in highly infiltrative, syngeneic glioma models, and intravenously administered hEGFRvIII-CD3 bi-scFv localized to these orthotopic tumors.Conclusions: We have developed a clinically translatable bispecific antibody that redirects human T cells to safely and effectively treat malignant glioma. On the basis of these results, we have developed a clinical study of hEGFRvIII-CD3 bi-scFv for patients with EGFRvIII-positive malignant glioma. Clin Cancer Res; 24(15); 3611-31. ©2018 AACR.


Subject(s)
CD3 Complex/antagonists & inhibitors , ErbB Receptors/antagonists & inhibitors , Glioma/drug therapy , Immunotherapy , Animals , Antibodies, Bispecific/pharmacology , CD3 Complex/immunology , Cell Line, Tumor , ErbB Receptors/immunology , Female , Gene Expression Regulation, Neoplastic/immunology , Glioma/immunology , Glioma/pathology , Humans , Lymphocyte Activation/drug effects , Lymphocyte Activation/immunology , Male , Mice , Recombinant Proteins/genetics , Recombinant Proteins/pharmacology , Single-Chain Antibodies/immunology , Single-Chain Antibodies/pharmacology , T-Lymphocytes/drug effects , T-Lymphocytes/immunology , Xenograft Model Antitumor Assays
6.
Am J Health Syst Pharm ; 72(18): 1567-71, 2015 Sep 15.
Article in English | MEDLINE | ID: mdl-26346212

ABSTRACT

PURPOSE: A case of serum sickness or serum sicknesslike reaction (SSLR) in a patient receiving rivaroxaban for venous thromboembolism (VTE) prophylaxis after undergoing elective right total knee arthroplasty (TKA) is reported. SUMMARY: A 61-year-old man arrived at the emergency department from a short-term rehabilitation facility 12 days after a right TKA with complaints of fever, chills, bilateral forearm pain, swelling in the extremities, and a diffuse erythematous rash with welts on his back. Rivaroxaban was initiated on postoperative day 1 for VTE prophylaxis and was discontinued on day 10 of therapy, when symptoms began to appear. His renal function was within normal limits; however, his alanine transaminase level was twice the upper limit of normal. The patient was admitted to the inpatient medical service and placed on intravenous fluids, subcutaneous heparin for VTE prophylaxis, supportive therapy for his symptoms, and his home medications. After 2 days of observation, the rheumatology and immunology services were consulted to assess the patient. Due to the patient's fever, myalgias, mild transaminitis, diffuse erythematous rash, and depressed total serum complement, it was determined that the patient had serum sickness secondary to treatment with rivaroxaban. The patient did not require any acute interventions, and symptoms resolved after 4 days of hospitalization. CONCLUSION: A 61-year-old man developed a possible case of serum sickness or SSLR 10 days after initiation of rivaroxaban for VTE prophylaxis after an elective TKA. Symptomatic improvement was observed after discontinuation of rivaroxaban, and no acute interventions were needed.


Subject(s)
Arthroplasty, Replacement, Hip , Factor Xa Inhibitors/adverse effects , Rivaroxaban/adverse effects , Serum Sickness/chemically induced , Humans , Male , Middle Aged , Postoperative Complications , Serum Sickness/therapy , Treatment Outcome , Withholding Treatment
7.
Clin Cancer Res ; 20(4): 972-84, 2014 Feb 15.
Article in English | MEDLINE | ID: mdl-24352643

ABSTRACT

PURPOSE: Chimeric antigen receptor (CAR) transduced T cells represent a promising immune therapy that has been shown to successfully treat cancers in mice and humans. However, CARs targeting antigens expressed in both tumors and normal tissues have led to significant toxicity. Preclinical studies have been limited by the use of xenograft models that do not adequately recapitulate the immune system of a clinically relevant host. A constitutively activated mutant of the naturally occurring epidermal growth factor receptor (EGFRvIII) is antigenically identical in both human and mouse glioma, but is also completely absent from any normal tissues. EXPERIMENTAL DESIGN: We developed a third-generation, EGFRvIII-specific murine CAR (mCAR), and performed tests to determine its efficacy in a fully immunocompetent mouse model of malignant glioma. RESULTS: At elevated doses, infusion with EGFRvIII mCAR T cells led to cures in all mice with brain tumors. In addition, antitumor efficacy was found to be dependent on lymphodepletive host conditioning. Selective blockade with EGFRvIII soluble peptide significantly abrogated the activity of EGFRvIII mCAR T cells in vitro and in vivo, and may offer a novel strategy to enhance the safety profile for CAR-based therapy. Finally, mCAR-treated, cured mice were resistant to rechallenge with EGFRvIII(NEG) tumors, suggesting generation of host immunity against additional tumor antigens. CONCLUSION: All together, these data support that third-generation, EGFRvIII-specific mCARs are effective against gliomas in the brain and highlight the importance of syngeneic, immunocompetent models in the preclinical evaluation of tumor immunotherapies.


Subject(s)
Adoptive Transfer , Astrocytoma/therapy , Brain Neoplasms/therapy , ErbB Receptors/metabolism , Receptors, Antigen, T-Cell/metabolism , Animals , Astrocytoma/immunology , Astrocytoma/metabolism , Brain Neoplasms/immunology , Brain Neoplasms/metabolism , Cell Line, Tumor , ErbB Receptors/immunology , Humans , Mice , Neoplasm Transplantation , Single-Chain Antibodies/metabolism , T-Lymphocytes/immunology , T-Lymphocytes/transplantation
8.
Mol Ther ; 20(2): 391-7, 2012 Feb.
Article in English | MEDLINE | ID: mdl-22086230

ABSTRACT

Millions of individuals are prescribed platelet inhibitors, such as aspirin and clopidogrel, to reduce their risk of thrombosis-related clinical events. Unfortunately many platelet inhibitors are contraindicated in surgical settings because of their inherent bleeding risk complicating the treatment of patients who require surgery. We describe the development of a potent antiplatelet agent, an RNA aptamer-termed Ch-9.14-T10 that binds von Willebrand factor (VWF) with high affinity and inhibits thrombosis in a murine carotid artery damage model. As expected, when this potent antiplatelet agent is administered, it greatly increases bleeding from animals that are surgically challenged. To improve this antiplatelet agent's safety profile, we describe the generation of antidotes that can rapidly reverse the activity of Ch-9.14-T10 and limit blood loss from surgically challenged animals. Our work represents the first antidote controllable antiplatelet agent, which could conceivably lead to improved medical management of patients requiring antiplatelet medication who also need surgery.


Subject(s)
Aptamers, Nucleotide/pharmacology , Oligonucleotides/pharmacology , Platelet Activation/drug effects , Platelet Aggregation Inhibitors/pharmacology , Animals , Antidotes/administration & dosage , Antidotes/pharmacology , Aptamers, Nucleotide/administration & dosage , Aptamers, Nucleotide/toxicity , Base Sequence , Cellulose/pharmacology , Cyclodextrins/pharmacology , Hemorrhage/drug therapy , Mice , Mice, Inbred C57BL , Molecular Sequence Data , Oligonucleotides/administration & dosage , Platelet Aggregation Inhibitors/administration & dosage , Thrombosis/drug therapy , von Willebrand Factor/chemistry , von Willebrand Factor/genetics , von Willebrand Factor/metabolism
9.
Blood ; 118(11): 3003-12, 2011 Sep 15.
Article in English | MEDLINE | ID: mdl-21768296

ABSTRACT

Lymphodepletion augments adoptive cell transfer during antitumor immunotherapy, producing dramatic clinical responses in patients with malignant melanoma. We report that the lymphopenia induced by the chemotherapeutic agent temozolomide (TMZ) enhances vaccine-driven immune responses and significantly reduces malignant growth in an established model of murine tumorigenesis. Unexpectedly, despite the improved antitumor efficacy engendered by TMZ-induced lymphopenia, there was a treatment related increase in the frequency of immunosuppressive regulatory T cells (T(Regs); P = .0006). Monoclonal antibody (mAb)-mediated inhibition of the high-affinity IL-2 receptor α (IL-2Rα/CD25) during immunotherapy in normal mice depleted T(Regs) (73% reduction; P = .0154) but also abolished vaccine-induced immune responses. However, during lymphodepletion, IL-2Rα blockade decreased T(Regs) (93% reduction; P = .0001) without impairing effector T-cell responses, to augment therapeutic antitumor efficacy (66% reduction in tumor growth; P = .0024). Of clinical relevance, we also demonstrate that anti-IL-2Rα mAb administration during recovery from lymphodepletive TMZ in patients with glioblastoma reduced T(Reg) frequency (48% reduction; P = .0061) while permitting vaccine-stimulated antitumor effector cell expansion. To our knowledge, this is the first report of systemic antibody-mediated T(Reg) depletion during lymphopenia and the consequent synergistic enhancement of vaccine-driven cellular responses, as well as the first demonstration that anti-IL-2Rα mAbs function differentially in nonlymphopenic versus lymphopenic contexts.


Subject(s)
Antibodies, Monoclonal/pharmacology , Interleukin-2 Receptor alpha Subunit/antagonists & inhibitors , Lymphocyte Depletion/methods , Lymphopenia/immunology , T-Lymphocytes, Regulatory/drug effects , Adult , Animals , Antibodies, Monoclonal/therapeutic use , Antibodies, Monoclonal, Humanized/pharmacology , Antibodies, Monoclonal, Humanized/therapeutic use , Antineoplastic Agents, Alkylating/therapeutic use , Brain Neoplasms/immunology , Brain Neoplasms/therapy , Cancer Vaccines/therapeutic use , Cells, Cultured , Combined Modality Therapy , Dacarbazine/analogs & derivatives , Dacarbazine/therapeutic use , Daclizumab , Drug Evaluation, Preclinical , Glioblastoma/immunology , Glioblastoma/therapy , Humans , Immunoglobulin G/pharmacology , Immunoglobulin G/therapeutic use , Immunotherapy/methods , Interleukin-2 Receptor alpha Subunit/immunology , Lymphopenia/pathology , Mice , Mice, Inbred C57BL , Mice, Transgenic , Middle Aged , Substrate Specificity/drug effects , Substrate Specificity/immunology , T-Lymphocytes, Regulatory/cytology , T-Lymphocytes, Regulatory/immunology , Temozolomide , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...